Soleno Therapeutics, Inc.
SLNOUnlisted companySoleno Therapeutics, Inc. in brief
Soleno Therapeutics, Inc. is an unlisted company in the Biotechnology industry, based in California, USA. It was founded in 1999. In its latest reported year it had sales of $0 M and a net loss of $25 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Soleno Therapeutics, Inc. timeline
- 1999
- 🏁· approximateFounded
- 2014
- 🔔· approximateInitial public offering on Nasdaq
Events of Soleno Therapeutics, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Soleno Therapeutics, Inc.
- Acquisitions and changes
- No longer listed: ticker SLNO is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #3,590 (Jan 2020) · #3,419 (Jan 2021) · #5,095 (Jan 2022) · #5,509 (Dec 2022) · #4,673 (Jul 2023) · #1,951 (Jan 2024) · #480 (Mar 2026)
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-25 M
Mutual funds holding Soleno Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 26,523 | $1 M | — | 0.77% | — | Apr 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Markets and events: Soleno Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-05-15 23:50 UTC, code D, resumed 04:00 UTC
- 2026-04-06 10:55 UTC, code T3, resumed 11:30 UTC
- 2025-03-26 20:03 UTC, code T3, resumed 22:45 UTC
Fails to deliver
- : 201 shares at $53.01
- : 64,409 shares at $53.01
- : 64,482 shares at $53.01
- : 194,854 shares at $52.99
- : 34,067 shares at $52.95
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Where Soleno Therapeutics, Inc. operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for Soleno Therapeutics, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Lobbying by Soleno Therapeutics, Inc.#
$200 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues4 reports
Lobbying firms hired in 2025
THE KPM GROUP DC LLC $200 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $220 K | $220 K | 6 |
| 2025 | $200 K | — | 4 |
| 2024 | $210 K | — | 4 |
| 2023 | $140 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Soleno Therapeutics, Inc.” and “SOLENO THERAPEUTICS, INC.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Soleno Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $150 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Business Systems ManagerInformation Technology Project Managers | 1 | $150 K |
Where: Redwood City, CA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Soleno Therapeutics, Inc.
FDA drug approvals: Soleno Therapeutics, Inc.#
1 approved applications held; 1 approvals and 0 new uses in 2025.
| Approved | Drug | Kind |
|---|---|---|
| 2025-03-26 | Vykat XrDiazoxide Choline · NDA216665 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (SOLENO), so they follow acquisitions
How Soleno Therapeutics, Inc. compares in Biotechnology
- Revenue$0 M · higher than 0% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Soleno Therapeutics, Inc.🇺🇸 | $2.0 B | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Mar 8, 2026 (last known)
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Soleno Therapeutics, Inc.? Verify and update this profile — free
Show Soleno Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.